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Abstract
Background: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a promising yet not
curative approach in castration-resistant (CR) prostate cancer (PC). Rational combination therapies may improve
treatment efficacy. Here, we explored the effect of androgen receptor blockade (ARB) on PSMA expression
visualized by PET and its potential additive effect when combined with 177Lu-PSMA RLT in a mouse model of
prostate cancer.
Methods: Mice bearing human CRPC (C4-2 cells) xenografts were treated with 10 mg/kg enzalutamide (ENZ), with
50 mg/kg bicalutamide (BIC), or vehicle (control) for 21 days. PSMA expression was evaluated by 68Ga-PSMA11 PET/
CT and quantified by flow cytometry of tumor fine needle aspirations before treatment and on days 23, 29, 34, and
39 post-therapy induction. For the RLT combination approach, mice bearing C4-2 tumors were treated with 10 mg/
kg ENZ or vehicle for 21 days before receiving either 15 MBq (84 GBq/μmol) 177Lu-PSMA617 or vehicle. DNA
damage was assessed as phospho-γH2A.X foci in tumor biopsies. Reduction of tumor volume on CT and survival
were used as study endpoints.
Results: Tumor growth was delayed by ARB while 68Ga-PSMA11 uptake increased up to 2.3-fold over time when
compared to controls. ABR-induced upregulation of PSMA expression was confirmed by flow cytometry. Phospho-
γH2A.X levels increased 1.8- and 3.4-fold at 48 h in response to single treatment ENZ or RLT and ENZ+RLT,
respectively. Despite significantly greater DNA damage and persistent increase of PSMA expression at the time of
RLT, no additional tumor growth retardation was observed in the ENZ+RLT group (vs. RLT only, p = 0.372 at day 81).
Median survival did not improve significantly when ENZ was combined with RLT.
Conclusion: ARB-mediated increases in PSMA expression in PC xenografts were evident by 68Ga-PSMA11 PET
imaging and flow cytometry. 177Lu-PSMA617 effectively decreased C4-2 tumor size. However, while pre-treatment
with ARB increased DNA damage significantly, it did not result in synergistic effects when combined with RLT.
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Introduction
The therapeutic landscape of castration-resistant (CR)
prostate cancer (PC) is changing. Recent introduction of
second-line androgen receptor blockade (ARB) has im-
proved the quality of life and patient survival. For in-
stance, enzalutamide (ENZ) increased median survival
by 2.2 months [1] and 4.8 months [2], respectively, when
compared to placebo.
The development of highly selective radiolabeled li-
gands binding to prostate-specific membrane antigen
(PSMA) opened up an additional therapeutic option
(PSMA-targeted radioligand therapy (RLT)) [3] that has
been exploited in more than 1000, mainly CRPC, pa-
tients worldwide, often in combination with basic ARB.
ARB and androgen withdrawal transcriptionally upregu-
late PSMA expression and enhanced the effect of a
PSMA-antibody drug conjugate [4–8]. Higher PSMA
levels might lead to increased binding of PSMA-targeting
agents and thus delivery of higher RLT tumor doses. How-
ever, the longitudinal effects of ARB-mediated increases in
PSMA on the therapeutic efficacy of PSMA-targeted radi-
oligand therapy have not been investigated.
Accordingly, we designed this study to (i) explore the
kinetics of ABR-induced changes in PSMA-expression
and (ii) investigate the potential additive effects of ARB
(ENZ) and 177Lu-PSMA617 RLT in a mouse model of PC.
Methods
Cell culture
C4-2 (kind gift of G. Thalmann, University of Bern,
Switzerland) is a human prostate cancer cell line reflect-
ing androgen-independent disease [9]. C4-2 expresses
robust and high levels of PSMA at the cell surface [10].
Cells were cultured in Rosewell Park Memorial Institute
(RPMI) 1640 medium supplemented with 10% fetal bo-
vine serum at 37 °C and 5% CO2. Cells were routinely
checked for mycoplasma contamination using the
MycoAlert PLUS mycoplasma detection kit (Lonza).
Mice
All animal studies were approved by the UCLA Animal
Research Committee (ARC; # 2005-090). Intact (non-ca-
strate) male, 6-week-old Scid mice were housed under
pathogen-free conditions. Water and food were provided
ad libitum. Mice were injected subcutaneously with 5 × 106
cells in matrigel into the shoulder region. Tumor growth
was monitored by computed tomography (CT). Animals
were sacrificed upon reaching any of the termination cri-
teria specified in the ARC protocol, including apathy, ul-
ceration, severe weight loss, or other signs of deteriorating
condition. The study protocol is outlined in Fig. 1.
Positron emission tomography/computed tomography
(PET/CT)
68Ga-PSMA11 (5 μg precursor) was obtained from the
UCLA Biomedical Cyclotron. Static PET/CT images were
acquired 60 min after the tail vein injection of approxi-
mately 1.1 MBq 68Ga-PSMA11 using the pre-clinical
Genisys 8 PET/CT scanner [11] (Sofie Biosciences). Image
acquisition time was 10 min. Attenuation-corrected im-
ages were reconstructed using maximum-likelihood ex-
pectation maximization with 60 iterations. The following
parameters were applied for CT imaging: 40 kVp,
Fig. 1 Experimental design. a Investigation of ARB (ENZ vs. bicalutamide (BIC) vs. vehicle)-mediated PSMA upregulation in C4-2 xenografts. b
Testing efficacy of pre-treatment with ENZ before PSMA-RLT in C4-2 tumors. DNA damage was assessed 4 h, 2 and 4 days post RLT by flow
cytometric quantification of phospho-γH2A.X in FNA tumor biopsies
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190 mA, 720 projections, and 55-ms exposure time per
projection.
Tumors were delineated on ≥ 7 axial CT images and
were encompassed in a volume of interest. Tumor
volume was calculated using OsiriX Imaging Software
(Version 3.9.3; Pixmeo SARL). The volume of interest
from CT was copied to the PET dataset to calculate the
mean and maximum percentage injected activity/gram
(%IAmean/g and %IAmax/g).
Fine needle aspiration (FNA) biopsy of mouse tumors
For serial monitoring of PSMA expression, tumor
samples were acquired by fine needle aspiration biopsy
[10, 12, 13]. Syringes were filled with 500 μl PBS, and a
25-G needle was attached. To account for tumor hetero-
geneity, tumor material was aspirated at three different
sites within the same tumor and flushed out as one sam-
ple. Cell suspensions were used for flow cytometric ana-
lysis of PSMA or phospho-γH2A.X expression.
Flow cytometry
Single-cell suspensions were stained with an
anti-hPSMA-APC antibody (clone REA408; 2.5 μl/test;
Miltenyi Biotech) for 30 min at 4 °C. Samples were fixed
and permeabilized using the Cytofix/Cytoperm kit from
BD and stained with an anti-phospho-γH2A.X-FITC
antibody (1:800, 20 min, RT, dark; Millipore) and DAPI
to analyze DNA damage. Samples were measured on a
5-laser LSRII cytometer (Beckton Dickinson) and ana-
lyzed using FlowJo software (Tri Star).
ARB
Mice were treated with 10 mg/kg ENZ [4], with 50 mg/
kg BIC (both drugs: MedChem Express), or vehicle (1%
labrasol/1% Tween-80/30% transcutol/68% PEG-200)
per oral gavage for 21 days.
Radioligand therapy with 177Lu-PSMA617
Non-carrier-added lutetium-177 trichloride was obtained
from isotope technologies Garching GmbH, Germany.
The precursor PSMA-617 was obtained from ABX
GmbH, Germany. Radiolabeling was performed at the
UCLA Biomedical Cyclotron Facility. Mice received a
single injection of 177Lu-PSMA617 (15 MBq; 84 GBq/
μmol) or 0.9% saline (vehicle control) per tail vein injec-
tion, respectively. The activity of 177Lu-PSMA617 was
chosen based on a preliminary dose escalation study. In
C4-2 tumors, 15 MBq 177Lu-PSMA617 was the lowest
activity we tested resulting in a significant tumor growth
inhibition compared to the control group. Therefore,
15 MBq 177Lu-PSMA617 were considered to be a
sub-optimal dose that is suitable to investigate potential
synergistic treatment effects in this model.
Experimental design
Assessing temporal changes in PSMA expression
We investigated ARB-induced effects on PSMA cell sur-
face expression (Fig. 1a). C4-2 tumors were established
in Scid mice (5 mice/treatment group, see below). At
day 19 ± 1 (baseline), PSMA expression was assessed by
68Ga-PSMA11 uptake by PET/CT and flow cytometry of
FNA tumor biopsies. Mice were then randomized into
three groups receiving enzalutamide, bicalutamide, and
vehicle, respectively, for 21 days. ENZ and BIC are clin-
ically used for treatment of mCRPC and castration sensi-
tive PC, respectively. To investigate ARB-induced PSMA
expression kinetics, changes in PSMA levels were
assessed by 68Ga-PSMA11 PET/CT and flow cytometry
on days 23, 29, 34, and 39 after tumor induction. These
time points were chosen based on our preliminary data
indicating that maximal PSMA induction could be ob-
served ~ 25 days after start of ARB (i.e., ~ 3 days after
cessation of ARB treatment; Additional file 1: Figure S1).
Investigating the efficacy of combined ARB and 177Lu-RLT
The results from the first part of the study indicated that
a 21-day ENZ regimen increased C4-2 tumor PSMA ex-
pression at least up to days 34–39 peaking around days
23–29 (see result below). Based on these findings, we
tested the potential additive effects of ENZ and
177Lu-PSMA617 RLT in C4-2 tumors as follows (Fig. 1b):
C4-2 tumors were induced in Scid mice. On day 20,
mice were randomized into two groups treated with
ENZ (n = 20) or vehicle (n = 20) for 21 days (analogous
to the above study). Two days after the end of treatment
(day 23, i.e., at the time of maximal ENZ-induced PSMA
levels) mice were further randomized into RLT or ve-
hicle subgroups (n = 10 mice/subgroup). DNA damage
was assessed 4 h, 48 h, and 96 h post RLT by flow cyto-
metric quantification of phospho-γH2A.X in FNA tumor
biopsies. Treatment efficacy was determined by tumor
volume changes on serial CT and by survival.
All interventions were conducted in a blinded fashion.
Statistics
Data were analyzed by readers blinded to the type of
intervention. Data are presented as mean ± standard de-
viation (SD) or median and range as appropriate.
Two-way ANOVA without correction for multiple com-
parisons (Fisher’s LSD) was used to compare different
groups. Survival was analyzed by the Kaplan-Meyer
method and one-way ANOVA without correction for
multiple testing (Fisher’s LSD). P < 0.05 was considered
statistically significant. GraphPad Prism (version 7,
GraphPad Software, Inc.) was used for all statistical
analyses.
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Results
PSMA expression in C4-2 xenografts by 68Ga-PSMA11 PET
imaging
Tumor growth was delayed by ARB in the C4-2 model
(at day 39, p = 0.009 (ENZ) and p = 0.005 (BIC); Fig. 3a,
Additional file 2: Figure S2). 68Ga-PSMA11 tumor up-
take tended to increase over time in all mice, peaking at
day 23 and slightly decreasing thereafter yet remaining
above baseline throughout the observation period (days
34–39 post ARB induction). The mean fold increase in
%IAmean/g (compared to baseline) at day 23 was 3.2 ± 0.9
(vehicle), 7.4 ± 7.2 (ENZ; p = 0.018 compared to vehicle),
and 4.2 ± 12.8 (BIC; p = 0.591), respectively (Fig. 3b;
Additional file 3: Table S1). For temporal changes in
PSMA expression as estimated from 68Ga-PSMA 11 im-
ages, see Fig. 2 and 3b.
PSMA expression by flow cytometry
PSMA expression per cell was quantified using flow cytom-
etry from tumor biopsies obtained after each PET/CT scan.
Relative PSMA levels in C4-2 tumors peaked at day 29
(MFI compared to baseline) and were 0.9 ± 0.3 (vehicle),
25.0 ± 21.2 (ENZ; p = 0.032 compared to vehicle), and 21.8
± 30.1 (BIC; p = 0.051 compared to vehicle) (Fig. 3c; Add-
itional file 3: Table S1).
Efficacy of RLT combined with ARB
As increased PSMA expression might lead to increased
tumor RLT doses, we pre-treated mice bearing C4-2 tu-
mors with ENZ before 177Lu-PSMA617 treatment. We se-
lected ENZ over BIC due to its stronger PSMA induction.
Please note that RLT was given 2 days after the last
ENZ dose (day 23), as our experiments showed that
PSMA expression remains elevated for 14–19 days after
ENZ treatment termination (Figs. 2 and 3; Additional
file 1: Figure S1).
Pre-treatment with ENZ enhanced RLT-induced DNA damage
Treatment with ENZ, RLT, or the combination of ENZ
and RLT (ENZ+RLT) induced DNA damage in C4-2 tu-
mors. The number of phospho-γH2A.X foci peaked 48 h
post-administration of RLT (Fig. 4; Additional file 4:
Table S2).
When compared to vehicle, phospho-γH2A.X levels
increased 1.8-fold at 48 h in both the ENZ-only and
RLT-only groups and 3.4-fold in ENZ+RLT group
(ENZ-only: p = 0.017; RLT-only: p = 0.051; ENZ+RLT:
p < 0.0001). Phospho-γH2A.X levels were highest in
the ENZ+RLT group (p ≤ 0.0005 vs. ENZ-only and
RLT-only). Phospho-γH2A.X foci decreased to base-
line in the ENZ, RLT, and ENZ+RLT groups after
96 h.
ENZ-induced PSMA upregulation and DNA damage did
not translate into additional tumor growth retardation
RLT retarded tumor growth when compared to the
groups receiving vehicle or ENZ only (Fig. 5a;
Additional file 2: Figure S2 and Additional file 5:
Table S3). Tumor growth differed significantly start-
ing on day 34 (vehicle vs. RLT: p = 0.003; vehicle vs.
ENZ+RLT: p = 0.005; ENZ vs. RLT or ENZ+RLT: p <
0.0001; vehicle vs. ENZ: p = 0.027). Pre-treatment
with ENZ before RLT did not retard tumor growth
further within our observation period (RLT vs. ENZ
+RLT, p = 0.372 at day 81; Fig. 5a, b).
Fig. 2 68Ga-PSMA11 PET/CT. C4-2 tumor-bearing mice were imaged
with 68Ga-PSMA11 PET/CT on days 0, 23, 29, 34, and 39 post start of
therapy with vehicle (top row), BIC (middle), or ENZ (bottom row).
Representative PET/CT images of 1 mouse per treatment group
are shown
Lückerath et al. EJNMMI Research            (2018) 8:96 Page 4 of 9
Conditioning with ENZ before RLT does not significantly
improve survival
Median survival following RLT was 34 (range 19–62), 41
(range 25–49), 71 (range 54–81), and 81 (range 62–81)
days in the ENZ-only, vehicle, RLT-only, and ENZ+RLT
groups, respectively (Fig. 5c). Thus, RLT alone or com-
bined with ENZ prolonged survival significantly when
compared to vehicle (p < 0.0001). However, combining
RLT with ENZ only tended to improve survival in the
ENZ+RLT group when compared to RLT alone. The
mean survival difference was 10 days (RLT vs. ENZ
+RLT, p = 0.08). It should be noted that a reliable sur-
vival analysis could not be performed as on day 81 all
remaining mice (3/10 in the RLT group; 8/11 in the ENZ
+RLT group) had to be sacrificed per veterinarian in-
struction, due to worsening mouse condition (e.g., ulcer-
ation of tumor, tumor size).
Discussion
The major hypothesis tested in our study was whether
increased levels of PSMA as induced by ARB result in
enhanced tumor targeting by 177Lu-PSMA617. As an-
drogen receptor suppresses PSMA transcription [14], its
inhibition with enzalutamide might lead to PSMA up-
regulation and, consequently, to a more effective treat-
ment of tumors with 177Lu-PSMA617.
We therefore investigated in a mouse model of prostate
cancer (i) the effect of ARB on PSMA expression over
time and (ii) the effects of ARB on the efficacy of
177Lu-PSMA617 RLT. Our results indicate that a 21-day
regimen of ENZ increases PSMA expression in C4-2 xe-
nografts that peaks around days 23–29 and is maintained
even after cessation of ENZ administration. However,
ENZ-induced PSMA expression does not retard tumor
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Fig. 3 ARB increases PSMA at the tumor cell surface. Tumor volume
of C4-2 (a) tumors was determined by CT (ENZ vs. vehicle, p = 0.05;
BIC vs. vehicle, p = 0.02). 68Ga-PSMA11 PET signal (%IAmean/g) in C4-2
(b) tumors (ENZ vs. vehicle, p = 0.02; BIC vs. vehicle, p = n.s.). PSMA
mean fluorescent intensity (MFI) is shown for each group (ENZ vs.
vehicle, p = 0.03; BIC vs. vehicle, p = n.s.) (c). The fold-change during
ARB treatment, related to the pre-treatment volume is shown. Data
are shown as mean ± SD. Asterisks indicate significance
Fig. 4 Pre-treatment with ENZ increases 177Lu-PSMA617-induced DNA
damage. Phospho-γH2A.X levels were flow cytometrically quantified in
FNA tumor biopsies 4 h, 48 h, and 96 h following administration of
177Lu-PSMA617 or vehicle, respectively. The fold-change in phospho-
γH2A.X compared to baseline (day before RLT) is shown as mean ± SD.
Asterisks indicate significance in ENZ+RLT-treated tumors compared to
baseline (ENZ+RLT: 0 vs. 4 h, p = 0.003; 0 vs. 48 h, p < 0.0001)
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growth more profoundly than 177Lu-PSMA617 alone.
Furthermore, survival was not significantly improved.
First, we established ARB regimens with BIC or ENZ
which effectively delayed tumor growth and induced a
transient increase in PSMA expression in human prostate
cancer xenografts in vivo. PSMA levels peaked 2–8 days
(days 23–29 after ENZ start) after cessation of ARB treat-
ment. Thus, when treated with ENZ for 21 days, PSMA
levels remained above baseline for another 13–18 days
(days 34–39 after ENZ start). This provided the rationale
for administrating RLT on day 23 (see below).
The increases in 68Ga-PSMA11 tumor uptake in
ARB-treated animals over controls were small (max. ~
2-fold). Both the small increment and the PSMA kinetics
corroborate and extend previous studies investigating
the effect of androgen receptor inhibition on PSMA
levels and PSMA-targeted imaging [4–7]. These studies
reported enhanced PSMA expression in PC xenograft
mouse models (i) upon androgen deprivation (6 days
treatment) using 64Cu-J591 PET on day 7 (an antibody
targeting the extracellular domain of PSMA) [4] and (ii)
following orchiectomy or a 7-day regimen of apaluta-
mide using 68Ga-PSMA11 PET on day 7 [5]. The latter
study also reports increased PSMA levels in a patient
following a 30-day ARB therapy. Only one study investi-
gated PSMA levels after ARB (ENZ) removal in vitro [7].
Following a 21-day treatment with ENZ, PSMA levels
peaked around day 21 and remained elevated (compared
to untreated cells) 4–7 days after ENZ discontinuation.
Importantly, this study demonstrated increased efficacy
of PSMA antibody-drug conjugates with increasing
PSMA expression.
Second, RLT and ENZ+RLT significantly delayed
tumor growth and improved survival (compared to
ENZ-only and vehicle). In addition, pre-treatment with
ENZ led to more profound DNA damage (phospho--
γH2A.X foci) compared to RLT alone. This is in line
with in vitro studies reporting that treatment with ENZ
combined with irradiation [15, 16] or the poly (ADP-Ri-
bose) polymerase inhibitor olaparib [17] increased the
number of phospho-γH2A.X foci resulting from either
treatment (X-ray or olaparib) alone.
Although this would be expected to improve thera-
peutic efficacy, pre-treatment with ENZ did not result in
additional tumor growth retardation when RLT was
compared to ENZ+RLT. An accurate survival analysis
was not possible as on day 81 all remaining mice (3/10
in the RLT group; 8/10 in ENZ+RLT) had to be sacri-
ficed (compare last paragraph of result section).
While ENZ efficiently reduced tumor growth (Fig. 3a),
tumors rapidly regrew in the ENZ-only group after ter-
mination of ENZ treatment (Fig. 5a shows tumor size
change from the time after completion of ENZ and be-
fore RLT). This might suggest that ARB is only effective
A
B
C
Fig. 5 Efficacy of combined ARB and 177Lu-PSMA617 radioligand
therapy. Tumor volume was determined by CT. The fold-change in
tumor volume after RLT (day 1) administration related to the tumor
volume immediately prior to RLT (day 0) is shown. The last dose of
ENZ was given at day 0. Data are represented as mean ± SD.
a Tumor volume change in all groups. Asterisks indicate
significance in vehicle and ENZ groups vs. RLT and ENZ+RLT
groups, respectively (****p < 0.0001; **p < 0.01). b Tumor volume
change in the RLT and ENZ+RLT groups (p = not significant).
c Kaplan-Meyer plot for survival
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during treatment. However, as shown in Figs. 2 and 3b
and c, increased PSMA expression persisted after cessa-
tion of ENZ up to day 34, i.e., almost 2 weeks after end
of ENZ therapy. In fact, PSMA levels peaked between 23
and 29 days after start of enzalutamide treatment
(Fig. 3b, c). 177Lu-PSMA617 radioligand therapy was
performed on day 23 (i.e., 2 days after the last dose of
ENZ), at a time when ENZ-induced PSMA expression
peaked. 177Lu-PSMA617 binds to PSMA-expressing tu-
mors within hours [18]. It is then rapidly internalized
[19]. Unbound 177Lu-PSMA617 is excreted via the kid-
neys. Therefore, we ascertained high PSMA expression
levels at the time of RLT administration. Maintaining
high PSMA expression beyond the time of RLT is thus
likely less (if at all) relevant for RLT efficacy. It remains
unclear whether ARB-induced increases in PSMA ex-
pression might have been insufficient to enhance RLT
efficacy. While we did not perform biodistribution stud-
ies to determine if the increased PSMA levels led to a
higher tumor uptake of 177Lu-PSMA617, preclinical
evaluation of 68Ga-PSMA11/177Lu-PSMA617 by
Umbricht et al. demonstrated very similar uptake and in-
ternalization of the 68Ga- and 177Lu-ligand, respectively,
by PC-3-PIP cells [20]. Likewise, the %IA/g in PC3-PIP
tumors was comparable for 68Ga-PSMA11 and
177Lu-PSMA617. In a similar study, Weineisen et al. [21]
found that uptake and internalization of
68Ga/177Lu-PSMA I&T—a similarly used theranostic
pair of PSMA ligands—into LNCaP cells was almost
identical. Lastly, SUVmean on
68Ga-PSMA11 PET/CT
images correlated with absorbed dose in men with
mCRPC [22]. Therefore, we propose that the uptake of
177Lu-PSMA617 into C4-2 tumors can be inferred from
the uptake of 68Ga-PSMA11. Our data (Figs. 2 and 3)
thus suggest that tumors conditioned with ENZ took up
more 177Lu-PSMA617 than tumors without
ENZ-induced PSMA upregulation. However, the actual
absorbed dose of 177Lu-PSMA617 in tumor or organs
cannot be calculated based on 68Ga-PSMA11 PET im-
ages, because the PET images only give information
about the tracer activity. Future studies will need to de-
fine the relationship between the degree of target ex-
pression, tumor-absorbed dose, and RLT efficacy.
An alternative or additional explanation for the lack of
synergy is based on the notion that AR signaling has
been implicated in DNA damage repair [23–25]. In the
setting of RLT, AR-triggered repair might protect tumor
cells from cell death; its impairment by ARB could thus
synergize with RLT. However, radiation causes the acti-
vation of several DNA damage repair pathways that act
in parallel [26]. As we did not observe an enhancement
of RLT by ARB, either (i) impairment of AR-triggered
repair might not be a critical determinant of RLT effi-
cacy on its own or (ii) the ENZ-mediated AR blockade
ceased with discontinuation of the ENZ administration.
The latter might imply the need for conditioning plus
continuation of ARB under RLT to first increase PSMA
expression and, subsequently, block repair of DNA dam-
age once it occurs.
Finally, it is possible that surgical castration or castra-
tion plus ENZ would have had a greater impact on AR
signaling and, consequently, PSMA expression, tumor
growth, and (AR-mediated) DNA damage repair. How-
ever, Evans et al. and Hope et al. directly compared the
impact of surgical castration vs. treatment with
anti-androgen (10 mg/kg ENZ and 10 mg/kg apaluta-
mide, respectively) on PSMA levels and tumor growth
[4, 5]. While both interventions decreased tumor growth
to a similar extent, upregulation of PSMA was stronger
following treatment with anti-androgens.
Combination therapies will be required to enhance the
effectiveness of RLT. For instance, a current randomized
phase III trial investigates the combination of abirater-
one and the alpha emitter Radium 223 (NCT02043678)
in mCRPC. Another prospective trial (e.g.,
ANZCTR12615000912583) combines second-line ARB
in conjunction with 177Lu-PSMA617. Finally, a recently
started trial in Australia combines RLT with DNA dam-
age response inhibitors (NCT03307629).
While we failed to show improved tumor growth re-
tardation with ENZ+RLT, a beneficial survival benefit
cannot be ruled out with certainty. First, mice had to be
sacrificed on day 81, mostly due to tumor ulceration.
Thus, it is possible that survival benefits in the combin-
ation therapy group may have been missed. Secondly, re-
sponses to RLT combinations may differ between the
current and other murine models. We selected the
current model as C4-2 reflects the clinically relevant
CRPC [9]. As ENZ upregulated PSMA in C4-2 tumors
more potently than BIC, it was chosen as the condition-
ing regimen. Furthermore, it remains to be determined
if multiple (vs. single) injections of 177Lu-PSMA617
would enhance synergism with a PSMA-inducing drug.
As PSMA levels started to decline around days 34–39,
testing this hypothesis would have required either (i) to
repeat the cycle of ENZ conditioning followed by
177Lu-PSMA617 a few weeks after the first cycle or (ii)
to continuously administer ENZ until a further injection
of 177Lu-PSMA617 could safely be given. In the current
setting, the prerequisites for a potential positive impact
of multiple 177Lu-PSMA617 administrations on treat-
ment outcome would include that in scenario (i) subse-
quent cycles would lead to the same PSMA surge as
observed after a single 21-day ENZ regimen and that in
scenario (ii) continuous treatment with ENZ would
maintain elevated PSMA levels.
Mice in the present study were treated with a single
injection of 15 MBq 177Lu-PSMA617 (specific activity
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84 GBq/μmol) which corresponds to 0.6 GBq/kg body
wt in a 25 g mouse. This activity is sub-optimal for treat-
ing C4-2 tumors with RLT (our unpublished observa-
tions) and should allow the detection of potential
synergistic effects of treatment combinations. Clinical
protocols currently registered at clinicaltrials.gov use 4–
6 cycles 177Lu-PSMA with cumulative activities ranging
from 14 (4 × 3.7 GBq) to 51 GBq (6 × 8.5 GBq) [27]. In
the recently opened prospective phase 3 randomized VI-
SION trial (NCT03511664), patients receive up to 6 cy-
cles with 7.4 ± 10% GBq 177Lu-PSMA617 each; assuming
an average weight of 80 kg, men thus receive 0.08–
0.10 GBq/kg bodyweight 177Lu-PSMA617 per cycle. This
is 6–7.5 times lower than the activity administered to
the mice in our study. However, considering the cumula-
tive activity patients receive over ≤ 6 cycles (maximum
39.96–48.84 GBq in the VISION trial), an 80-kg man
would be treated with a total activity of 0.50–0.61 GBq/
kg bodyweight. Therefore, the cumulative activity tested
in clinical protocols and in our study is similar.
The differences in respective fold increase in PSMA ex-
pression measured by flow cytometry vs. 68Ga-PSMA11
PET-imaging in this study cannot be explained. However,
a limited dynamic range of 68Ga-PSMA11 PET signal in-
tensity (acquired with the Genisys 8 PET/CT) has previ-
ously been observed [10]. In that study, PSMA expression
(as quantified by flow cytometry from FNA tumor biop-
sies) and 68Ga-PSMA PET signal correlated at lower
PSMA levels; this correlation was lost at higher PSMA ex-
pression levels.
Conclusion
In summary, we demonstrate that ENZ upregulates
PSMA expression in C4-2 tumors that can be monitored
non-invasively in vivo by 68Ga-PSMA11 PET imaging.
PSMA levels peaked at about 3–4 weeks after the start
of ARB therapy. 177Lu-PSMA617 effectively decreases
C4-2 tumor size. Pre-treatment with ARB followed by
177Lu-PSMA617 increases DNA damage significantly.
However, no additive effect on tumor growth or survival
was demonstrated. Clinical studies are needed to deter-
mine whether ARB and RLT can yield synergistic effects
in patients with CRPC.
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Additional file 1: Figure S1. PSMA expression kinetics following ARB. C4-2
tumors were induced in Scid mice. Mice received enzalutamide, bicalutamide,
or vehicle for 21 days (n= 5/group). PSMA expression was estimated by
68Ga-PSMA11 PET/CT on days 1, 8, 15, 19, 22, 25, 28, 32, and 36 post start of
treatment. Data are represented as mean ± SD. (PDF 32 kb)
Additional file 2: Figure S2. Absolute tumor volumes immediately
prior to RLT (day 0) and following RLT are shown as mean ± standard
deviation for each treatment group. Apparent drops in mean tumor
volumes (e.g., vehicle and ENZ-only groups at day 49, RLT-only group at
day 74) result from euthanasia of mice that was mandatory due to wors-
ening mouse condition. Usually, these mice were those with the largest
tumors in the respective groups. (PDF 29 kb)
Additional file 3: Table S1. Fold-change in tumor volume,
68Ga-PSMA11 uptake, and PSMA levels as assessed by flow cytometry in
C4-2 tumors. Mean ± SD are given. (DOCX 15 kb)
Additional file 4: Table S2. Fold-change in phospho-γH2A.X levels
following PSMA-RLT. Mean ± SD are given. After 48 h, phospho-γH2A.X
levels are significantly higher in the ENZ+RLT groups than in the
ENZ-only (p = 0.017), RLT-only (p = 0.051), and vehicle (p < 0.0001) treated
groups, respectively. (DOCX 14 kb)
Additional file 5: Table S3. Fold-change in C4-2 tumor volume
following PSMA-RLT. Mean ± SD are given. (DOCX 14 kb)
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